Back to Authors

Kumar, Shaji

https://orcid.org/0000-0001-5392-9284

A5026574827 | I1330342723

Mayo Clinic

Mayo Clinic

Citations 1268

Trial in Progress: REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase Ib Multi-Cohort Study of Combination Regimens for Patients with Relapsed/Refractory Multiple Myeloma

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 4444-4446

10.1182/blood-2022-157713

Artificial Intelligence-Enhanced Models to Predict Light Chain Amyloidosis from Patients with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 7230-7232

10.1182/blood-2022-168119

Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 1830-1832

10.1182/blood-2022-168930

Validation of a Novel Rac1 Inhibitor As Potent Secdrug Against Activating Ras Mutant and Drug-Resistant Multiple Myeloma

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 4249-4250

10.1182/blood-2022-164501

AI-Enabled Screening for Drug Repurposing in Monoclonal Gammopathy of Undetermined Significance

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 7842-7843

10.1182/blood-2022-169376

Single-Cell Dissection of Primary Quadruplet- and Triplet-Resistant Multiple Myeloma

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9978-9979

10.1182/blood-2022-162679

A Phase 1 First-in-Human Study of Abbv-383, a BCMA × CD3 Bispecific T-Cell-Redirecting Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple Myeloma

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 4401-4404

10.1182/blood-2022-167008

Persistance or Reappearance of Serum Monoclonal Protein Detected By Mass Spectrometry Is a Major Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 2347-2348

10.1182/blood-2022-167430

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 7297-7300

10.1182/blood-2022-163494

Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 1360-1362

10.1182/blood-2022-160038